Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-15
2006-08-15
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S259100, C514S266210, C544S012000, C544S013000, C544S281000, C544S284000
Reexamination Certificate
active
07091200
ABSTRACT:
This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by Formula I:wherein Z is —C(O)— or —S(O)2—, X is carbon or nitrogen, Y is carbon, and X-Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
REFERENCES:
patent: 3146233 (1964-08-01), Hurmer
patent: 3275625 (1966-09-01), Muller et al.
patent: 3892858 (1975-07-01), Novello
patent: 3960861 (1976-06-01), Danilewicz et al.
patent: 4029780 (1977-06-01), Nishimura et al.
patent: 4044136 (1977-08-01), Danilewicz et al.
patent: 4171361 (1979-10-01), Dillard et al.
patent: 4686228 (1987-08-01), Campbell et al.
patent: 4766211 (1988-08-01), Zink et al.
patent: 5064833 (1991-11-01), Ife et al.
patent: 5488049 (1996-01-01), Costa et al.
patent: 5773434 (1998-06-01), Larson et al.
patent: 6030968 (2000-02-01), Gall et al.
patent: 6103738 (2000-08-01), Collis et al.
patent: 6337332 (2002-01-01), Carpino
patent: 6492358 (2002-12-01), Sui et al.
patent: 6562854 (2003-05-01), Church et al.
patent: 6566367 (2003-05-01), Bakthavatchalam et al.
patent: 2002/0119969 (2002-08-01), Ebdrup et al.
patent: 2003/0109519 (2003-06-01), Sturis
patent: 2004/0029859 (2004-02-01), Blagg et al.
patent: 2757925 (1979-06-01), None
patent: 1062357 (1967-03-01), None
patent: WO 98/30560 (1998-07-01), None
patent: WO 00/55143 (2000-09-01), None
Gupta, et al., “Drugs Acting on the Central Nervous System. Syntheses of Substituted Quinazolones and Quanazolines and Triazepino- andTriazocinoquina-zolones,”J. Med. Chem., 1968, 392-395, 11(2).
Leonardi, et al., “Synthesis Pharmacological Evaluation, and Structure—Activity Relationship and Quantitative Structure—Activity Relationship Studies on Novel Derivatives of 2,4-Diamino-6,7-dimethoxyquinazoline α1-Adrenoceptor Antagonists”,J. Med. Chem., 1999, 427-437, 42.
Menziani, et al., “Relevance of Theoretical Molecular Descriptors in Quantitative Structure—Activity Relationship Analysis of α1-Adrenergic Receptor Antagonists,”Bioorg., Med. Chem., 1999, 2437-2451, 7(11).
Villalorgo, et al., “Solid-Phase Synthesis of 3H-Quinazolin-4-ones Based on an Aza Wittig-Mediated annulation Strategy”,Synlett, 1998, 1405-1407, 12.
Wollweber, et al., “3-Amino-2H-1,2,4-benzothiadiazin-1, 1-dioxide mit antihypertensiver und potentieller diabetogener Wirkung”,Arzneim.-Forsch., 1981, 279-88, 31(2).
Becker Cyrus Kephra
Caroon Joan Marie
Melville Chris Richard
Padilla Fernando
Pfister Jürg Roland
Green Grant D.
Syntex (U.S.A.) LLC
Truong Tamthom N.
Wilson James O.
LandOfFree
Quinazolone derivatives as alpha 1A/B adrenergic receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazolone derivatives as alpha 1A/B adrenergic receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazolone derivatives as alpha 1A/B adrenergic receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3619120